Fig. 5
Relative immune-associated gene expression in psoas muscle of wild-type (WT) C57Bl/6J and dysferlin-deficient BLA/J mice aged 5 months, without and with dexamethasone (Dex) treatment. A Complement C1q B Chain (C1qb); B Complement component 3 (C3); C Complement C3a Receptor 1 (C3ar1); D Complement component 4 (C4); E Complement component 5 (C5); F Complement C5a Receptor 2 (C5ar2); G Decay-accelerating factor 1 for complement (Daf1 or CD55); H Decay-accelerating factor 2 for complement B (Daf2 or CD55b); I Caspase 1 (Casp1); J NLR family pyrin domain containing 3 (Nlrp3). Skeletal actin (Acta1) was used as a reference gene to normalise gene expression values in the psoas muscle. Relative gene expression was calculated using the 2−ΔΔCT Method, and values were normalised to the untreated WT for each gene. Data were analysed by two-way ANOVA: **** BLA/J (± Dex) vs WT (± Dex) (p < 0.0001, strain effect); ## Dex-treated vs untreated (p < 0.01, treatment effect); ^, ^^, ^^^, ^^^^ significant difference between groups (p < 0.05, 0.01, 0.001, 0.0001, respectively, strain/treatment interaction effect). Data are log10 transformed and presented on a log10 y-axis scale as mean ± SD (n = 5–8)